Juergen Krause

Description

Details

NameJuergen Krause
PositionFaculty Member
Emailjukrause@upei.ca
Department(s)School of Business
Phone(902) 566-0340
BuildingMcDougall Hall 232
Websitehttp://www.upei.ca/business/juergen-krause

Juergen Krause

Biography

Dean; Director, Centre for Health and Biotech Management Research

Juergen Krause earned his Masters degree in Chemistry and his PhD degree in Biochemistry from the University of Konstanz, Germany and performed his postdoctoral studies at the University of Chicago, Illinois. Before moving into education, he spent 22 years in the Pharmaceutical and Biopharmaceutical industry. Juergen worked 18 years for Boehringer Ingelheim Pharmaceuticals in both the European and United States offices before joining Millennium Pharmaceuticals (now Takeda) in Cambridge, Massachusetts as Vice President of R&D Strategy & Operations in 2004. During his career, he served in several different operational and strategic capacities, holding senior and executive positions in research and development, manufacturing and quality management, project management, pipeline and portfolio management and strategy development. He also successfully championed global company initiatives and a number of industry/university collaborations and led alliances with other industry partners.

Dr. Krause joined the faculty of the UPEI School of Business in July 2008 as an Associate Professor and teaches mostly in the field of strategic management, project management and biotechnology.


Recent Citations


Subscribe to Juergen Krause's citation feed

Research Interests

  • Management of science and innovation
  • Biotech cluster formation and development
  • Change and opportunity in the global biotech industry
  • Best practices and strategic portfolio management in biopharmaceutical and biotech sectors
  • Improving cross functional R&D performance
  • Collaborations and alliance models

Other Scholars in School of Business

Citations

Step 1: Select your citations

TitleAuthor(s)
The degree of coupling of oxidative phosphorylation is varied physiologicallyKrause, J.; Klug, G.; Brdiczka, D.
Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in menMüller, T. H.; Weisenberger, H.; Brickl, R.; Narjes, H.; Himmelsbach, F.; Krause, J.
Localisation of fluorescence-labelled recombinant tissue-type Plasminogen activator (rt-PA) on thrombi in vitroKrause, J.; Deutsch, H.
Different neuropeptsde Y receptor subtypes in rat and rabbit vas deferensDoods, H. N.; Krause, J.
Endocytosis and intracellular processing of tissue-type plasminogen activator by rat liver cells in vivo.Stang, E.; Krause, J.; Seydel, W.; Berg, T.; Roos, N.
Microcompartmentation at the mitochondrial surfaceBrdiczka, D.; Knoll, G.; Riesinger, I.; Weiler, U.; Klug, G.; Benz, R.; Krause, J.
Porin pores of mitochondrial outer membranes from high and low eukaryotic cellsDe Pinto, V.; Ludwig, O.; Krause, J.; Benz, R.; Palmieri, F.
Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator.Tanswell, P.; Seifried, E.; Stang, E.; Krause, J.
BIBP 3226, the first potent and selective non-peptide Y1 receptor antagonistRudolf, K.; Eberlein, W.; Engel, W.; Beck-Sickinger, AG; Dollinger, H.; Esser, F.; Schnorrengerg, G.; Mihm, G.; Wieland, H. A.; Entzeroth, M.; Wienen, W.; Krause, J.; Doods, H. N.
Purification and characterization of the pore forming protein of yeast mitochondrial outer membraneLudwig, O.; Krause, J.; Hay, R.; Benz, R.
The structure and function of the pore in the mitochondrial external membrane / Untersuchungen zur Struktur und Funktion der Pore in der Mitochondrialen AubenmembranKrause, J.
Pharmacokinetics and isolated liver perfusion of carbohydrate modified recombinant tissue-type plasminogen activatorTanswell, P.; Schlüter, M.; Krause, J.
Evidence for carbohydrate-independent endocytosis of tissue-type plasminogen activator by liver cells.Stang, E.; Roos, N.; Schlüter, M.; Berg, T.; Krause, J.
The binding of glycerol kinase to the outer membrane of rat liver mitochondriaÖstlund, A. K.; Göhring, U.; Krause, J.; Brdiczka, D.
Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.Tanswell, P.; Heinzel, G.; Greischel, A.; Krause, J.
Strategic macro-environmental factor analysis for entry into the fish vaccines market in IndiaPallapothu, Mahendra Kumar; Krause, Juergen
Case study of interprovincial variations in patient access to Oncology drugsBallem, Katherine H. D.; Krause, Juergen
Pharmaco-dynamics and-kinetics of BIBU 52, a platelet glycoprotein (GP) IIb/IIIa antagonist, and its orally active prodrug BIBU 104 in manMüller, TH; Weisenberger, H.; Brickl, R.; Kirchner, M.; Narjes, H.; Himmelsbach, F.; Guth, B.; Krause, J.
Hepatic uptake of tissue-type plasminogen activator is saturableKrause, J.; Tanswell, P.
Nonlinear pharmacokinetics and isolated liver perfusion of carbohydrate-modified tissue-type plasminogen activatorTanswell, P.; Schluter, M.; Krause, J.
Tissue-type plasminogen activator and ovalbumin show colocalization after endocytosis in hepatic cells.Stang, E.; Krause, J.; Berg, T.; Roos, N.
Neuropeptide Y1 subtype pharmacology of a recombinantly expressed neuropeptide receptor.Krause, J.; Eva, C.; Seeburg, P. H.; Sprengel, R.
Saturability of clearance of t-PA in three animal species and isolated perfused rat liverTanswell, P.; Heinzel, G.; Greischel, A.; Seydel, W.; Krause, J.
Localisation of fluorescence labelled recombinant tissue-type plasminogen activator (rt-PA) on thrombi in vitroKrause, J.; Deutsch, H.
Properties of molecular variants of tissue-type plasminogen activatorKrause, J.; Tanswell, P.
Die molekularbiologischen Eigenschaften des Gewebetyp-plasminogenactivators und seiner VariantenTanswell, P.; Krause, J.
Characterization of the receptor mediating the hepatic catabolism of t-PASeydel, W.; Hoffmann, H.; Krause, J.
Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells.Seydel, W.; Stang, E.; Roos, N.; Krause, J.
Enrichment and biochemical characterization of boundary membrane contact sites from rat-liver mitochondria.Ohlendieck, K.; Riesinger, I.; Adams, V.; Krause, J.; Brdiczka, D.
Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybridsKrause, J.
Endocytosis and intracellular processing of t-PA by rat liver cellsSeydel, W.; Hoffmann, H.; Krause, J.
Alterations in liver mitochondrial function as a result of fasting and exhaustive exercise.Klug, G. A.; Krause, J.; Ostlund, AK; Knoll, G.; Brdiczka, D.
Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 xx in healthy volunteersNarjes, H.; Weisenberger, H.; Muller, TH; Deichsel, G.; Krause, J.
Optimizing productivity in a matrix structureKrause, J.
Characterization of muscarinic receptor in guinea pig uterus smooth muscleDoods, H. N.; Willim, K.; Krause, J.
The Prince Edward Island bioscience clusterCasper, S.; Krause, J.; MacNevin, A.
Aligning R&D and commercial to increase productivityKrause, J.
Balancing R&D and commercialization teams to maximize early market entryKrause, J.
Hepatic Endocytosis of Tissue-Type Plasminogen Activator with Special Reference to the Sinusoidal CellsWisse, E.; Knook, D. L.; ,
Pharmacokinetics of Human Tissue-Type Plasminogen ActivatorTanswell, P.; Seifried, E.; Krause, J.

Step 2: Preview or export the formatted citations

Theses

Step 1: Select your citations

Step 2: Preview or export the formatted citations

Metrics

TitleTimes viewedLast viewed
The degree of coupling of oxidative phosphorylation is varied physiologically - ir:430226923:30:06 2015-07-26
Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men - ir:432327413:39:30 2015-07-15
Localisation of fluorescence-labelled recombinant tissue-type Plasminogen activator (rt-PA) on thrombi in vitro - ir:429228323:34:04 2015-07-13
Different neuropeptsde Y receptor subtypes in rat and rabbit vas deferens - ir:420229204:20:32 2015-07-22
Endocytosis and intracellular processing of tissue-type plasminogen activator by rat liver cells in vivo. - ir:435526119:51:01 2015-07-23
Microcompartmentation at the mitochondrial surface - ir:416730405:45:19 2015-07-25
Porin pores of mitochondrial outer membranes from high and low eukaryotic cells - ir:418925817:25:32 2015-07-27
Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator. - ir:435924119:11:52 2015-07-27
BIBP 3226, the first potent and selective non-peptide Y1 receptor antagonist - ir:434824411:26:18 2015-07-19
Purification and characterization of the pore forming protein of yeast mitochondrial outer membrane - ir:430426305:36:17 2015-07-27
The structure and function of the pore in the mitochondrial external membrane / Untersuchungen zur Struktur und Funktion der Pore in der Mitochondrialen Aubenmembran - ir:450726005:29:14 2015-07-21
Pharmacokinetics and isolated liver perfusion of carbohydrate modified recombinant tissue-type plasminogen activator - ir:435825102:11:26 2015-07-20
Evidence for carbohydrate-independent endocytosis of tissue-type plasminogen activator by liver cells. - ir:435626706:43:24 2015-07-17
The binding of glycerol kinase to the outer membrane of rat liver mitochondria - ir:432727415:09:03 2015-07-20
Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. - ir:435726620:56:16 2015-07-16
Strategic macro-environmental factor analysis for entry into the fish vaccines market in India - ir:442956403:37:04 2015-07-27
Case study of interprovincial variations in patient access to Oncology drugs - ir:415343412:14:10 2015-07-25
Pharmaco-dynamics and-kinetics of BIBU 52, a platelet glycoprotein (GP) IIb/IIIa antagonist, and its orally active prodrug BIBU 104 in man - ir:432429011:42:38 2015-07-27
Hepatic uptake of tissue-type plasminogen activator is saturable - ir:429522817:12:42 2015-07-17
Nonlinear pharmacokinetics and isolated liver perfusion of carbohydrate-modified tissue-type plasminogen activator - ir:436129614:44:03 2015-07-27
Tissue-type plasminogen activator and ovalbumin show colocalization after endocytosis in hepatic cells. - ir:435425810:00:19 2015-07-27
Neuropeptide Y1 subtype pharmacology of a recombinantly expressed neuropeptide receptor. - ir:429325403:20:02 2015-07-19
Saturability of clearance of t-PA in three animal species and isolated perfused rat liver - ir:436024401:27:28 2015-07-22
Localisation of fluorescence labelled recombinant tissue-type plasminogen activator (rt-PA) on thrombi in vitro - ir:430029404:33:57 2015-07-24
Properties of molecular variants of tissue-type plasminogen activator - ir:429623319:55:24 2015-07-27
Die molekularbiologischen Eigenschaften des Gewebetyp-plasminogenactivators und seiner Varianten - ir:455127717:20:00 2015-07-20
Characterization of the receptor mediating the hepatic catabolism of t-PA - ir:435127518:38:30 2015-07-27
Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells. - ir:435023802:36:44 2015-07-24
Enrichment and biochemical characterization of boundary membrane contact sites from rat-liver mitochondria. - ir:432624818:19:46 2015-07-27
Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids - ir:429124802:57:57 2015-07-24
Endocytosis and intracellular processing of t-PA by rat liver cells - ir:435226016:21:29 2015-07-23
Alterations in liver mitochondrial function as a result of fasting and exhaustive exercise. - ir:428929213:01:27 2015-07-27
Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 xx in healthy volunteers - ir:432527522:51:03 2015-07-26
Mastitis treatment decision system - ir:282253113:17:15 2015-07-27
Genetically modified crops - ir:3722107522:59:58 2015-07-27
Aquaculture industry analysis and market attractiveness of fish vaccines in India - ir:414153316:54:36 2015-07-27
Primary healthcare models - ir:871923012:45:28 2015-07-21
Optimizing productivity in a matrix structure - ir:429929200:31:18 2015-07-27
Characterization of muscarinic receptor in guinea pig uterus smooth muscle - ir:420324809:26:55 2015-07-26
The Prince Edward Island bioscience cluster - ir:418638104:47:41 2015-07-25
Aligning R&D and commercial to increase productivity - ir:429833613:58:58 2015-07-23
Balancing R&D and commercialization teams to maximize early market entry - ir:429732823:51:28 2015-07-26
Hepatic Endocytosis of Tissue-Type Plasminogen Activator with Special Reference to the Sinusoidal Cells - ir:436730719:37:41 2015-07-21
Pharmacokinetics of Human Tissue-Type Plasminogen Activator - ir:436233503:45:40 2015-07-27